WO2008033432A3 - Immune modulation by chemically modified ribonucleosides and oligoribonucleotides - Google Patents

Immune modulation by chemically modified ribonucleosides and oligoribonucleotides Download PDF

Info

Publication number
WO2008033432A3
WO2008033432A3 PCT/US2007/019873 US2007019873W WO2008033432A3 WO 2008033432 A3 WO2008033432 A3 WO 2008033432A3 US 2007019873 W US2007019873 W US 2007019873W WO 2008033432 A3 WO2008033432 A3 WO 2008033432A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligoribonucleotides
chemically modified
immune modulation
modified ribonucleosides
ribonucleosides
Prior art date
Application number
PCT/US2007/019873
Other languages
French (fr)
Other versions
WO2008033432A2 (en
Inventor
Jorg Vollmer
Stefan Bauer
Grayson B Lipford
Original Assignee
Coley Pharm Group Inc
Coley Pharm Gmbh
Jorg Vollmer
Stefan Bauer
Grayson B Lipford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Group Inc, Coley Pharm Gmbh, Jorg Vollmer, Stefan Bauer, Grayson B Lipford filed Critical Coley Pharm Group Inc
Publication of WO2008033432A2 publication Critical patent/WO2008033432A2/en
Publication of WO2008033432A3 publication Critical patent/WO2008033432A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

The invention relates to modified oligoribonucleotides with immunomodulatory activity. The invention encompasses treatment of autoimmune and infectious diseases using the oligonucleotides of the invention.
PCT/US2007/019873 2006-09-12 2007-09-12 Immune modulation by chemically modified ribonucleosides and oligoribonucleotides WO2008033432A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84383806P 2006-09-12 2006-09-12
US60/843,838 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033432A2 WO2008033432A2 (en) 2008-03-20
WO2008033432A3 true WO2008033432A3 (en) 2008-11-06

Family

ID=39047781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019873 WO2008033432A2 (en) 2006-09-12 2007-09-12 Immune modulation by chemically modified ribonucleosides and oligoribonucleotides

Country Status (1)

Country Link
WO (1) WO2008033432A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
SG177000A1 (en) 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
EP3006043B1 (en) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CN101454451A (en) 2003-10-30 2009-06-10 科勒制药有限公司 C-class oligonucleotide analogs with enhanced immunostimulatory potency
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR20080072934A (en) 2005-11-25 2008-08-07 콜리 파마슈티칼 게엠베하 Immunostimulatory oligoribonucleotides
MX2009003398A (en) 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
AU2010254550B2 (en) 2009-05-27 2015-10-15 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents
EP2470554B1 (en) 2009-08-26 2017-06-28 Selecta Biosciences, Inc. Compositions that induce t cell help
AU2011258156B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US9303258B2 (en) * 2011-04-05 2016-04-05 The Regents Of The University Of California Method and compositions comprising small RNA agonist and antagonists to modulate inflammation
AU2012290306B2 (en) 2011-07-29 2017-08-17 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2968510B1 (en) 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
US9828641B2 (en) 2013-08-01 2017-11-28 The Regents Of The University Of California Systemic genotoxicity as blood marker for allergic inflammation
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US20150374815A1 (en) 2014-06-25 2015-12-31 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
US10538769B2 (en) 2015-09-04 2020-01-21 Oregon State University Renal selective inhibition of cytochrome P450 3A5
WO2019207066A1 (en) * 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
JP2022544412A (en) 2019-08-14 2022-10-18 キュアバック アーゲー RNA combinations and compositions with reduced immunostimulatory properties
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232443A1 (en) * 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20030232443A1 (en) * 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression

Also Published As

Publication number Publication date
WO2008033432A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008033432A3 (en) Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2004112687A3 (en) Antiviral acylguanidine compounds and methods
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
EP1994984A4 (en) Carbon-based solid acid, catalyst comprising the solid acid, and reaction using the solid acid as catalyst
WO2005097825A3 (en) Bmp-7 variants with improved properties
WO2008127364A3 (en) Antiviral compounds and use thereof
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
EP1954788A4 (en) Combustion catalyst carriers and methods of using the same
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EP2076326A4 (en) Ce-zr-r-o catalysts, articles comprising the ce-zr-r-o catalysts and methods of making and using the ce-zr-r-o catalysts
MX2009011500A (en) Anti-mdl-1 antibodies.
WO2005079533A3 (en) Methods and compositions for mediating gene silencing
EP2354224A4 (en) Novel protein having fructosyl valyl histidine oxidase activity and modified product thereof, and use of the protein or the modified product
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
WO2007011639A3 (en) Catalytic immunoglobulins
WO2010011331A3 (en) Compositions and methods related to sirt1 function
WO2007057018A3 (en) Glucoamylase variants
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2007130616A3 (en) Polyamides for treating human papilloma virus
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010052559A8 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
ZA200806505B (en) Treatment of HIV
WO2007103584A3 (en) Polyamides for treating human papilloma virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838130

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838130

Country of ref document: EP

Kind code of ref document: A2